Literature DB >> 10605744

CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects.

M T Reding1, H Wu, M Krampf, D K Okita, B M Diethelm-Okita, N S Key, B M Conti-Fine.   

Abstract

These studies have begun to clarify the complex cellular mechanisms involved in the immune response to factor VIII. Although vigorous sensitization of CD4+ cells occurs in healthy subjects, the absence of clinically significant levels of inhibitor antibodies is likely related to the prompt down-regulation of the immune response. It may also be possible that the specific epitope repertoire recognized by CD4+ cells plays a role in the outcome of the immune response to factor VIII. Further characterization and comparison of the CD4+ repertoire in healthy subjects with that of hemophilia patients with and without inhibitors will help clarify which mechanism explains the absence of productive inhibitor synthesis in certain individuals. Also, it might identify CD4+ epitopes recognized by T helper cells that are essential for inhibitor synthesis. Additional studies to further characterize the role of Th1 and Th2 cells in the immune response to factor VIII may also be needed for the design of novel therapeutic strategies aimed at preventing inhibitor development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10605744

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  18 in total

Review 1.  Tolerance induction by viral in vivo gene transfer.

Authors:  Eric Dobrzynski; Roland W Herzog
Journal:  Clin Med Res       Date:  2005-11

2.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

3.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

Review 4.  Animal models of hemophilia.

Authors:  Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

5.  Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.

Authors:  Puneet Gaitonde; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  Eur J Pharm Sci       Date:  2014-10-20       Impact factor: 4.384

6.  T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.

Authors:  E A James; S D van Haren; R A Ettinger; K Fijnvandraat; J A Liberman; W W Kwok; J Voorberg; K P Pratt
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

7.  A shift towards a T cell cytokine deficiency along with an anti-inflammatory/regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients.

Authors:  D G Chaves; C Velloso-Rodrigues; C A Oliveira; A Teixeira-Carvalho; M M Santoro; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2010-09-15       Impact factor: 4.330

8.  HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII.

Authors:  Simon D van Haren; Eszter Herczenik; Anja ten Brinke; Koen Mertens; Jan Voorberg; Alexander B Meijer
Journal:  Mol Cell Proteomics       Date:  2011-04-05       Impact factor: 5.911

Review 9.  Immune response to FVIII in hemophilia A: an overview of risk factors.

Authors:  Kanjaksha Ghosh; Shrimati Shetty
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 10.  A cellular viewpoint of anti-FVIII immune response in hemophilia A.

Authors:  Sebastien André; Yann Meslier; Jordan D Dimitrov; Yohann Repessé; Srinivas V Kaveri; Sebastien Lacroix-Desmazes; Suryasarathi Dasgupta
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.